Venus Medtech Hangzhou Inc (2500) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Venus Medtech Hangzhou Inc stock HK$1.14, price HK$0.99, upside +15.2%, quality 42 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Venus Medtech Hangzhou Inc
2500 · HKThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range HK$0.9650 – HK$63.95 · fair‑value band HK$0.8500 – HK$1.42 · the HK$0.9900 price screens below the HK$1.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether Venus Medtech Hangzhou is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally.
Show moreShow less
The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis.
It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; and renal artery denervation ablation system for the treatment of hypertension.
In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Stock analysis
Venus Medtech Hangzhou Inc (2500) currently trades at HK$0.9900, while our estimate is HK$1.14, so the stock looks roughly fairly valued today (gap 13.2%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: HK$0.8500 (bear) to HK$1.42 (bull), the price of HK$0.9900 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Venus Medtech Hangzhou Inc reported revenue of 307M CNY in FY2025 versus 416M CNY in FY2021, a compound −7.3%/yr. Reported net income was −408M CNY in FY2025.
Key figures
Market cap HK$434M (≈ $55.3M) Micro · P/S ratio 1.72 · Net margin −133% · Return on equity −25.9% · Return on assets (EBIT) −11.1% (5-year average) · Operating margin −126% · Revenue (TTM) 255M CNY · Revenue growth (YoY) −27.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 72% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 15%, 2500 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 2500, get fair value alerts →
Compare Venus Medtech Hangzhou Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks
Valuation Multiplesvs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Stryker Corporation SYK | $309.64 | $343.63 | +11% | vs 2500 |
| Boston Scientific Corporation BSX | $44.34 | $48.77 | +10% | vs 2500 |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥179.40 | ¥197.34 | +10% | vs 2500 |
| DexCom, Inc DXCM | $83.33 | $91.66 | +10% | vs 2500 |
| STERIS plc STE | $264.32 | $281.90 | +7% | vs 2500 |
| GE HealthCare Technologies Inc GEHC | $83.02 | $69.92 | −16% | vs 2500 |
| Edwards Lifesciences Corporation EW | $107.15 | $81.94 | −24% | vs 2500 |
| Medtronic plc MDT | $102.86 | $74.90 | −27% | vs 2500 |
| Abbott Laboratories, ABT | $108.52 | $75.28 | −31% | vs 2500 |
| Koninklijke Philips N.V PHIA | €27.43 | €15.23 | −44% | vs 2500 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Venus Medtech Hangzhou Inc (2500) overvalued or undervalued?
What is the fair value of 2500?
What is the quality score of 2500?
What is the price target for Venus Medtech Hangzhou Inc (2500)?
What is the Venus Medtech Hangzhou Inc stock forecast for 2026?
What is the revenue of Venus Medtech Hangzhou Inc (2500)?
What is the intrinsic value of Venus Medtech Hangzhou Inc (2500)?
Is Venus Medtech Hangzhou Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2500?
How much is Venus Medtech Hangzhou Inc worth?
What do the bullish and bearish scenarios say about 2500?
How solid is the balance sheet of Venus Medtech Hangzhou Inc (2500)?
How far is 2500 from its 52-week high?
Which stocks are comparable to Venus Medtech Hangzhou Inc?
Is Venus Medtech Hangzhou Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Venus Medtech Hangzhou Inc (2500)?
What should I pay attention to with Venus Medtech Hangzhou Inc right now?
Key figures of Venus Medtech Hangzhou Inc
How large is the market capitalisation of Venus Medtech Hangzhou Inc (2500)?
What is the P/S ratio of Venus Medtech Hangzhou Inc (2500)?
What is the net margin of Venus Medtech Hangzhou Inc (2500)?
What is the return on equity of Venus Medtech Hangzhou Inc (2500)?
What is the EBIT return on assets of Venus Medtech Hangzhou Inc (2500)?
What is the operating margin of Venus Medtech Hangzhou Inc (2500)?
How fast is revenue growing at Venus Medtech Hangzhou Inc (2500)?
How much free cash flow does Venus Medtech Hangzhou Inc (2500) generate?
How much net debt does Venus Medtech Hangzhou Inc (2500) carry?
Watch Venus Medtech Hangzhou Inc in the live analysis
One click puts Venus Medtech Hangzhou Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.